Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 4.3% in the afternoon session after Canaccord Genuity ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...

Genetic testing company Natera (NASDAQ:NTRA). will be reporting results this Thursday afternoon. Here’s what investors should ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling ...

Natera's robust financial performance, driven by strong growth in its Women’s Health and Oncology segments, justifies its recent stock price surge and positive outlook. The company’s strategic ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top ...

When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...

Initial 2026 guidance calls for revenue of $2.62 billion to $2.70 billion, implying around 25% growth over 2025 when backing out true-ups. Natera is targeting gross margins of 63% to 65% while holding ...